"Didanosine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.
| Descriptor ID |
D016049
|
| MeSH Number(s) |
D03.633.100.759.590.616.130 D13.570.230.500.090 D13.570.583.616.130 D13.570.800.573.130
|
| Concept/Terms |
Didanosine- Didanosine
- Dideoxyinosine
- 2',3'-Dideoxyinosine
- 2',3' Dideoxyinosine
- ddI (Antiviral)
|
Below are MeSH descriptors whose meaning is more general than "Didanosine".
Below are MeSH descriptors whose meaning is more specific than "Didanosine".
This graph shows the total number of publications written about "Didanosine" by people in this website by year, and whether "Didanosine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Didanosine" by people in Profiles.
-
Willig JH, Westfall AO, Allison J, Van Wagoner N, Chang PW, Raper J, Saag MS, Mugavero MJ. Nucleoside reverse-transcriptase inhibitor dosing errors in an outpatient HIV clinic in the electronic medical record era. Clin Infect Dis. 2007 Sep 01; 45(5):658-61.
-
Ballardin M, Scarpato R, Kotwal GJ, Barale R. In vitro mutagenicity studies of the antiretrovirals AZT, Didanosine, and 3TC and a plant antiviral extract Secomet-V derived from the Trifollium species. Ann N Y Acad Sci. 2005 Nov; 1056:303-10.
-
Johnson MD, Chen J, Anderson BD. Investigation of the mechanism of enhancement of central nervous system delivery of 2'-beta-fluoro-2',3'-dideoxyinosine via a blood-brain barrier adenosine deaminase-activated prodrug. Drug Metab Dispos. 2002 Feb; 30(2):191-8.
-
Nusbaum NJ, Abraham T. Combination antiretroviral chemotherapy: a potential strategy in AIDS-related malignancy. Anticancer Drugs. 1996 Jan; 7(1):109-14.
-
Saitz R, Friedmann PD, Roberts MS. Continued zidovudine or didanosine for human immunodeficiency virus infection. N Engl J Med. 1992 Nov 26; 327(22):1598; author reply 1599.
-
Lai KK, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI). Ann Intern Med. 1991 Aug 15; 115(4):283-4.
-
Heagy W, Crumpacker C, Lopez PA, Finberg RW. Inhibition of immune functions by antiviral drugs. J Clin Invest. 1991 Jun; 87(6):1916-24.